Bristol-Myers Squibb has agreed to pay more than $2 billion to purchase Cardioxyl. The transaction, which is expected to be completed this year, will expand Bristol-Myers’ heart failure product portfolio to include Cardioxyl’s acute decompensated heart failure treatment CXL-1427, which is in midstage development.